2025. Comparative Study between combination therapy Empagliflozin–Sitagliptin and Empagliflozin–Alogliptin in addition to Metformin assessing the hypoglycemic effect on patients diagnosed with malignancy and poorly controlled Type 2 diabetes mellitus as comorbidity. Journal of Carcinogenesis. 24, 3 (Sep. 2025), 669–674. DOI:https://doi.org/10.64149/J.Carcinog.24.3.669-674.